Примери за използване на Neuraminidase inhibitors на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Common antiviral prescriptions include neuraminidase inhibitors.
What is the role of neuraminidase inhibitors in the treatment of influenza?
The H5N1 virus is expected to be susceptible to the neuraminidase inhibitors.
Safety of neuraminidase inhibitors against novel influenza A(H1N1) in pregnant and breastfeeding women.
Pharmacotherapeutic group: Antivirals for systemic use, neuraminidase inhibitors ATC code: J05AH03.
Viral===Neuraminidase inhibitors may be used to treat viral pneumonia caused by influenza viruses(influenza A and influenza B).
Ebilfumin contains oseltamivir,which belongs to a group of medicines named neuraminidase inhibitors.
Oseltamivir(eg Tamiflu, Oseltamivir):take the drug(class: neuraminidase inhibitors) at a dose of 75 mg, twice a day for 5 days.
Alpivab contains the active substance peramivir which belongs to a group of medicines called neuraminidase inhibitors.
The sensitivity of the viruses to the neuraminidase inhibitors Oseltamivir and Zanamivir was determined by a phenotypic method using fluorescent substrate MUNANA.
In severe cases associated with influenza A orB, the antiviral neuraminidase inhibitors may be administered.
Zanamivir(eg. Relenza): the drug(class: neuraminidase inhibitors) should be taken by inhalation at a dose of 10 mg every 12 hours, for 5 days.
Influenza attacks are generally treated with antiviral drugs containing neuraminidase inhibitors and M2 Protein inhibitors. .
Neuraminidase inhibitors must be administered very early since the replication of influenza virus in the respiratory track reaches its peak after 24-72 hours after infection.
According to the Centers for Disease Control and Prevention(CDC), neuraminidase inhibitors have a 70 to 90 percent success rate in preventing the flu.
In comparison to vaccines, the development of anti-influenza drugs has been slower,with amantadine being licensed in 1966 and, almost thirty years later, the next class of drugs(the neuraminidase inhibitors) being developed.
Oseltamivir and zanamivir are chemically related antiviral medications known as neuraminidase inhibitors that have activity against both influenza A and B viruses.
Antiviral resistance to neuraminidase inhibitors has been clinically negligible so far but is likely to be detected during widespread use during a pandemic.
The new recommendations highlight oseltamivir and zanamivir,which are neuraminidase inhibitors, and amantadine and rimantadine, which are M2 inhibitors. .
Adults hospitalised with H1N1 influenza during the 2009-2010 pandemic were 25% less likely to die from the disease if they were given antiviral drugs called neuraminidase inhibitors(NAIs) such as Tamiflu.
The pandemic virus is currently susceptible to both of these drugs(known as neuraminidase inhibitors), but resistant to a second class of antivirals(the M2 inhibitors). .
The clinical impact of substitutions associated with reduced susceptibility to zanamivir and other neuraminidase inhibitors is variable and may be strain-dependent.
Most swine influenza viruses have been susceptible to antiviral medications such as neuraminidase inhibitors(oseltamivir and zanamivir) and older antiviral drugs(amantadanes).
Neuraminidase inhibitor.
The H5N1 virus is likely prone to the neuraminidase inhibitor….
So they're a neuraminidase inhibitor.
Zanamivir is an inhibitor of influenza virus neuraminidase, an enzyme that releases viral particles from the plasma membrane of infected cells and promotes virus spread in the respiratory tract.
Peramivir is an inhibitor of influenza virus neuraminidase, an enzyme that releases viral particles from the plasma membrane of infected cells and is also important for viral entry into uninfected cells, which causes further spread of infectious virus in the body.
The active metabolite is a selective inhibitor of influenza virus neuraminidase enzymes, which are glycoproteins found on the virion surface.
However, the frequency of resistance to the neuraminidase inhibitor oseltamivir remains low(1-2%).